Clinical trials: System; Sclerosis
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy of PoNS in Reducing Symptoms of Multiple Sclerosis
The purpose of this pilot study is to determine whether a program involving both in-lab and at-home training using cranial nerve stimulation (CN-NINM) delivered via the tongue can reduce symptoms of multiple sclerosis (MS) and…
- Trial name
- NCT04496531
- Testing
- Portable Neuromodulation Stimulator
- Volunteers
- 14 people
- Sponsor
- Helius Medical Inc
Multiple Sclerosis
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis.
- Trial name
- NCT01764737
- Testing
- VX15/2503
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaccinex Inc.
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
The main purpose of this study is to evaluate the pharmacokinetics (PK) of ocrelizumab administered subcutaneously (SC) in children and adolescents aged 10 to <18 years with RRMS.
- Trial name
- Operetta III (NCT07503340)
- Testing
- Ocrelizumab co-formulated with rHuPH20
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Active Secondary Progressive Multiple Sclerosis
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
This is an observational, multicenter, single-arm, prospective study conducted in Italy
- Trial name
- ITASIA (NCT05376579)
- Testing
- siponimod
- Where
- 24 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
- Trial name
- PROOF (NCT00599274)
- Testing
- Interferon beta-1a
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 136 people
- Sponsor
- Biogen
Multiple Sclerosis
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple…
- Trial name
- NS-MSS (NCT01538225)
- Testing
- Sativex®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Almirall, S.A.
Relapsing-Remitting Multiple Sclerosis
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron.
- Trial name
- NCT00902135
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Germany
- Volunteers
- 702 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing Remitting
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity…
- Trial name
- NCT01080040
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Amyotrophic Lateral Sclerosis, ALS
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04165850
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Multiple Sclerosis, Relapsing-Remitting
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- SCLEROLYM (NCT02427776)
- Testing
- Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
- Where
- 3 sites in Belgium
- Volunteers
- 2 people
- Sponsor
- Imcyse SA
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Multiple Sclerosis
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
The primary objective of the study is to assess the effect of long-term treatment with prolonged-release fampridine (BIIB041) 10 mg twice daily on the physical component scale (PCS) of the Short Form 36 Health Status…
- Trial name
- ENABLE (NCT01480076)
- Testing
- Fampridine
- Where
- 59 sites in Australia, Belgium and 7 more
- Volunteers
- 901 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00230074
- Testing
- TCH346
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Novartis
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Relapsing-remitting Multiple Sclerosis
Extension Study of MT-1303
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT01890655
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 17 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 367 people
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis
Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis
The goal of this clinical trial is to learn if intravenous infusion of allogeneic mesenchymal stem cell (MSC)-derived exosomes can slow disability progression and improve neurological function in adults with progressive multiple…
- Trial name
- NCT07146087
- Testing
- MSC-Derived Exosomes
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Biocells Medical
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals